Go to BioCentury homepage
Print this Print this
Welcome to BCIQ: BioCentury Online Intelligence.
Free access to this and other abridged company profiles is provided to all subscribers to SciBX: Science-Business eXchange.

Please explore the profile and if you wish to find out more about BCIQ - please Click Here

Kissei Pharmaceutical Co. Ltd.

Print preview Print preview

(Tokyo:4547)

Collapse Summary

General Information
 Location Nagano, Japan
 Region
 Country Japan
 Business Category Pharmaceuticals
 Year Founded 1946
 Website www.kissei.co.jp
 Development Status Market (drug) (01/30/2007)

Archive Items are loading
Collapse Summary

Pipeline Information
Disease CategoryResearchPhase IPhase I/IIPhase IIPhase II/IIIPhase IIIRegistrationApprovedMarketed
Cancer

1

-

-

-

-

-

-

-

-

Endocrine

-

1

-

-

-

-

-

-

1

Genitourinary

-

-

-

2

-

-

-

1

-

Hematology

-

-

-

-

1

-

-

-

-

Inflammation

-

-

-

1

-

-

-

-

-

Other

-

-

-

-

-

-

-

-

1

Total

1

1

-

3

1

-

-

1

2

Pipeline Details - Originated and out-licensed products (6 records)

Product Names

Disease Category

Standard Indication

Partners

Milestones

Latest Stage of Development

Glufast (Brand), KAD-1229 (Compound #), mitiglinide (Generic), Glinsuna (Informal), Glufast (Informal)

Endocrine

Diabetes

Elixir Pharmaceuticals Inc.

 

Marketed

KGT-1681 (Compound #)

Endocrine

Diabetes

 

 

Phase I
More

Pipeline Details - In-licensed products (3 records)

Product NamesDisease CategoryStandard IndicationIn-licensed fromMilestonesLatest Stage of DevelopmentRights

JR-013 (Compound #)

Hematology

Anemia

JCR Pharmaceuticals Co. Ltd.

 

Phase II/III

Development

Salagen (Brand), KSS-694 (Compound #), pilocarpine (Generic), Salagen (Other)

Other

Xerostomia

Eisai Co. Ltd.

 

Marketed

Commercialization
More